LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc.

LENZ·NASDAQ

$7.01

-0.14%
HealthcareBiotechnology

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

At a Glance

Live Snapshot
Market Cap$219.79M
EPS-2.8500
P/E Ratio-2.46
Earnings Date07/29/2026

lenz

Net Receivables

Last Annual Value

2.43M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Competitors Analysis of Net Receivables

LENZ · NASDAQ
CompanyNet Receivables
CAGR 3Y
CAGR 5Y
CAGR 10Y
2.43M
N/AN/AN/A 
SVRA logo
Savara Inc.
NASDAQ:SVRA
1.25M
7.7%1.9%3.7%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
0.00
N/AN/AN/A
25.35M
217.1%660.0%N/A
1.75M
-0.5%14.2%9.7%
39.23M
187.2%86.0%55.5%
25.50M
-22.9%-26.3%N/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Fair Value Envelope

LENZ · NASDAQ

Our analysis suggests that LENZ has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.01, this represents a potential HIDDEN relative to our calculated worth for LENZ Therapeutics, Inc..

Intrinsic Value
Current Price: $7.01